SCHEMBL6569004

SCHEMBL6569004

O=C(N/N=C\c1cc(Cl)ccc1O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.75
KDM4E B2RXH2 7/20 0.75
LMNA P02545 4/20 0.75
HTT P42858 4/20 0.75
SMN1; SMN2 Q16637 4/20 0.75
POLB P06746 3/20 0.75
PTBP1 P26599 2/20 0.75
TDP1 Q9NUW8 1/20 0.75
KDM1A O60341 3/20 0.63
MAPT P10636 6/20 0.63
MEN1 O00255 6/20 0.62
RAB9A P51151 4/20 0.62
NPC1 O15118 3/20 0.62
KLF5 Q13887 1/20 0.62
PSMD14 O00487 1/20 0.61
MMP2 P08253 1/20 0.61
BLM P54132 1/20 0.61
MITF O75030 1/20 0.61
GPR174 Q9BXC1 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6569011 1.00 KMT2A (0.75) KMT2AKDM4ELMNAHTTSMN1; SMN2
SCHEMBL686554 0.91 KDM1A (0.69) KMT2AKDM4ELMNAHTTSMN1; SMN2
SCHEMBL6571437 0.88 KDM4E (0.78) KMT2AKDM4ELMNAHTTSMN1; SMN2
SCHEMBL6571440 0.88 KDM4E (0.78) KMT2AKDM4ELMNAHTTSMN1; SMN2
SCHEMBL684540 0.88 KDM1A (0.77) KMT2AKDM4ELMNAHTTSMN1; SMN2
SCHEMBL684639 0.87 KDM1A (0.81) KMT2AKDM4ELMNAHTTSMN1; SMN2
SCHEMBL6751416 0.87 KDM1A (0.81) KMT2AKDM4ELMNAHTTSMN1; SMN2
SCHEMBL6751419 0.87 KDM1A (0.81) KMT2AKDM4ELMNAHTTSMN1; SMN2
SCHEMBL6571712 0.86 KMT2A (1.00) KMT2AKDM4ELMNAHTTSMN1; SMN2
SCHEMBL684556 0.86 KMT2A (1.00) KMT2AKDM4ELMNAHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110963-A1 Novel hydrazones ARPIDA AG (CH) 2004-06-10 US claimed
US-20040110963-A1 Novel hydrazones ARPIDA AG (CH) 2004-06-10 US disclosed
EP-1404644-A2 NOVEL HYDRAZONES Arpida AG, (CH) 2004-04-07 EP disclosed
WO-2002070464-A2 HYDRAZONES AND THEIR THERAPEUTIC USE ARPIDA AG (CH) 2002-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110963-A1 Novel hydrazones H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HK1, MPO KMT2A 3368/4885KDM4E 3228/4885LMNA 4156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.